US Officials Explore AI Company Equity Stakes Ahead of OpenAI and Anthropic IPO Plans 
Apollo and Blackstone Complete $35 Billion Anthropic AI Infrastructure Financing Deal 
Alphabet Unveils $80 Billion Capital Raise to Accelerate AI Expansion, Secures $10 Billion Backing from Berkshire Hathaway 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
Italy’s ITA Airways Weighs Legal Action Against Pratt & Whitney Over Grounded Airbus Fleet 
SpaceX Targets Record-Breaking $75 Billion IPO at $135 Per Share in Historic Market Debut 
TSMC Sees Strong AI-Driven Growth as Demand for Advanced Chips Continues to Surge 
Insignia Financial Shares Hit 3-Year High Amid Bain and CC Capital Bidding War 
South Korea Weighs AI Profit Sharing as Samsung and SK Hynix Earnings Surge 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors 
South Korea to End Short-Selling Ban as Financial Market Uncertainty Persists 
China's Refining Industry Faces Major Shakeup Amid Challenges 
MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
How the UK’s rollback of banking regulations could risk another financial crisis 
Naver Stock Jumps on NVIDIA Partnership to Build South Korea’s AI Infrastructure 
KiwiSaver shakeup: private asset investment has risks that could outweigh the rewards 
Tempus AI Inc (NASDAQ:TEM) shares surged over 18% to $41.62 in after-hours trading following a disclosure by former House Speaker Nancy Pelosi. Pelosi revealed in a recent filing that she had purchased 50 call options on the artificial intelligence-focused precision medicine firm. The options, priced between $50,000 and $100,000, have a $20 strike price and expire on January 16, 2026.
Pelosi’s disclosure also included call options in tech giants Alphabet Inc (NASDAQ:GOOGL), NVIDIA Corporation (NASDAQ:NVDA), and Amazon.com Inc (NASDAQ:AMZN).
The rally comes despite Tempus being down about 12% since its public listing in June 2024. The stock faced pressure last week when a major shareholder sold $33.1 million worth of shares, even after Tempus reported strong 2024 earnings. However, the company flagged a slowdown in contract research organization revenues, sparking some investor caution.
Sentiment around Tempus has turned highly bullish on trading platforms like Stocktwits, with discussions about the stock spiking after Pelosi’s disclosure. The platform reported increased interest and optimism, which contributed to the stock’s strong rally.
Tempus leverages artificial intelligence technology for precision medicine applications, and its growth potential continues to attract attention from prominent investors. This latest move by Pelosi, a well-known and closely watched figure in the investment community, has added momentum to the stock, drawing increased scrutiny from retail and institutional investors alike.
As interest in AI and precision medicine grows, Tempus is positioned as a key player, gaining visibility and market attention.
